Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a 5-year survival rate of only 6%. Although the cytosine analog gemcitabine is the drug commonly used to treat PDAC, chemoresistance unfortunately renders the drug ineffective. Thus, strategies that can decrease this resistance will be...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Xu, Dapeng, Cobb, Michael G., Gavilano, Lily, Witherspoon, Sam M., Williams, Daniel, White, Catherine D., Taverna, Pietro, Bednarski, Brian K., Kim, Hong Jin, Baldwin, Albert S., Baines, Antonio T.
Формат: Artigo
Язык:Inglês
Опубликовано: Landes Bioscience 2013
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3813565/
https://ncbi.nlm.nih.gov/pubmed/23760491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24343
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы